6Cummings SR,Karft DB,Harris F,et al.Improvement in spine bone density and reduction in risk of vertebral fracture during treatment wuth antiresorptive drugs.Am J Med,2002,112:281-289.
7Sarkar S,Mitlak BH,Wong M,et al.Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.J Bone Miner Res,2002,17:1-10.
8Hulley S,Grady D,Bush T,et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.Heart and Estrogen/progestin Replacement study (HERS) Research Groupas.JAMA,1998,280:605-631.
9Rossouw JE,Anderson GL,Prentice RL,et al.Risk and benefite of estrogen plus progestin in healthy postmenopausal women:principal resuits From the Women's Health Initiative randomized controlled trial.JAMA,2002,288:321-333.
10Chestnut CH 3rd,Silverman S,Andriano K,et al.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of 0steoporotic fractures study.PROOF Study Group.Am J Med,2000,109:267-276.
5Dawson-Hughes B, Heaney R P, Holick M F, et al. Estimates of op- timal vitamin D status[J] Osteoporos Int,2005,16 (7) :713-716.
6Recker R R, Marin F, lsh-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis [J] J Bone Miner Res,2009,24(8) :1358-1368.
7HernOndez M V, Guafiabens N, Alvarez L,et al. hnmunocytochemi- cal evidence on the effects of glucocorticoids on type I collagen syn- thesis in human osteoblastic cells [ J]. Calcif Tissue Int, 2004,74 (3) :284-293.
8Crofton P M, Evans N, Stephen R. Serum CrossLaps compared with other markers of hone turnover in severely malnourished children before and after refeeding[J], Clin Chem ,2003,49 ( 1 ) : 192-195.
9Tascioglu F, Colak O, Armagan O, et al. The treatment of osteoporo- sis in patients with rheumatoid arthr it is receiving glucocorticoids:a comparison of alendronate and intranasal salmon calcitonin [ J 1. Rheumatol Int ,2005,26 (1) :21-29.
10Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP-5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients [ J ]. Cal- cif Tissue Int,2008,82 (4) :278-287.
